An efficacy and safety of mirabegron in Parkinson's disease patients with storage symptoms refractory to antimuscarinics.

Trial Profile

An efficacy and safety of mirabegron in Parkinson's disease patients with storage symptoms refractory to antimuscarinics.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2016 New trial record
    • 16 Sep 2016 Primary endpoint (Subjective improvement in urinary symptoms) has not been met, as per an abstract presented at the 46th Annual Meeting of the International Continence Society
    • 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top